Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, pharmacokinetics and preliminary efficacy of GR3027 in healthy volunteers and cirrhotic patients with covert hepatic encephalopathy
2016-003651-30Phase 2Completed
- Sponsor
- Umecrine Cognition
- Start
- Oct 2016
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of golexanolone in hepatic encephalopathy (HE) and Cirrhosis (6 arms), sponsored by Umecrine Cognition. Primary endpoint: Safety and tolerability. Started Oct 2016; status: completed.
02
Drugs
golexanolone
03
Conditions
hepatic encephalopathy (HE)Cirrhosis
Beyond the preview
Go deeper on 2016-003651-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003651-30.